Benitec Biopharma Gross Profit

Benitec Biopharma (BNTC) currently reports a gross profit of $-240K as of June 2026. That compares with $280K in the prior-year period — down 187.4% year over year. That is below the sector sector average of $760M. Use the charts on this page to explore Benitec Biopharma's gross profit history and peer comparisons.

Benitec Biopharma's gross profit decreased from $280K to $-240K — a 187.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Benitec Biopharma's gross profit of $-240K is lower than the its sector sector average of $760M. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Benitec Biopharma reported $-240K in gross profit as of June 2026. That compares with $280K in the prior-year period — down 187.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $-240K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $760M. From there, open related valuation or income-statement pages for Benitec Biopharma, and consider following BNTC for alerts when major investors trade the stock.